Companies that foster an environment that supports professional growth are more likely to thrive and successfully adopt digital innovation. Here are the 100 best places to work in Europe—and how they stay that way.

<p>Zoetis ranks 93 on Fortune 100 Best Companies to Work For – Europe 2026 list.</p>

Fortune 100 Best Companies To Work For – Europe

With a combined revenue of $21 trillion and $2.1 trillion in profits, the 2026 Fortune 500 is the definitive list of America's largest companies.

Fortune 500

Almost $20 trillion in revenue—and a record-breaking $1.87 trillion in profits. Introducing the 2025 Fortune 500, the definitive list of the biggest companies in America.

Industries included in the sector are insurance and managed care, medical products and facilities, pharmacy services, and pharmaceutical companies.

Fortune Sector Leaders: Health Care

The Fortune 500, in its 70th year in 2024, ranks the biggest U.S. companies by revenue.

The Fortune 500, in its 69th year in 2023, ranks the biggest U.S. companies by revenue.

Fortune's annual list dedicated to the idea that business is uniquely suited to address society’s biggest challenges.

CTW.1122.Zoetis

The business of veterinary care technology is both a lucrative and an impactful one—animal health company Zoetis brought in $7.8 billion in revenue in 2021 while developing vaccines and treatments for livestock and pets. Zoetis’s geographic footprint is as wide as its technological scope; the company oversees the production of veterinary biodevices and genetic tests from their design to manufacturing while providing services and products to over one hundred countries. In 2017, Zoetis launched its African Livestock Productivity and Health Advancement (ALPHA) Initiative with a grant from the Bill &amp; Melinda Gates Foundation; ALPHA now provides veterinary technology and training resources to veterinarians and farmers in sub-Saharan Africa. The effort addresses food insecurity by giving small farmers the resources and training to sustainably keep livestock healthy. ALPHA currently operates 16 serology labs across Uganda, Nigeria, Tanzania, and Ethiopia. So far, 11 million chickens and over 45,000 cows have been tested for diseases through these labs. Even more important is the educational element of the initiative: In all, 26,000 farmers and veterinarians have been trained in livestock care and an estimated 1.3 million people have been reached through train-the-trainer programs. That education includes “an emphasis on training women,” senior director of sustainability and innovation communications Christina Lood told <em>Fortune</em>. The Zoetis Foundation has also recently focused on empowering America’s small-business dairy farmers to utilize sustainable technology.

Change the World

This year’s Fortune 500 marks the 68th running of the list.

This year’s Fortune 500 marks the 67th running of the list.

F500-2021-431-Zoetis

The drug company, which was spun off from Pfizer in 2013, bills itself as the world's leading animal health company, producing medicine and vaccinations for pets and livestock. Those businesses proved relatively pandemic-proof in 2020, as Zoetis's revenue and profit grew by 7% and 9%, respectively.

This year's Fortune 500 marks the 66th running of the list.

F500-2020-472-Zoetis

Zoetis develops and manufactures animal-health medicines and vaccines whose customers include veterinarians, pet owners, and livestock farmers.

This year's Fortune 500 marks the 65th running of the list.

This year's Fortune 500 marks the 64th running of the list.

This year's Fortune 500 marks the 63rd running of the list.

This year's Fortune 500 marks the 62nd running of the list.

This year's Fortune 500 marks the 61st running of the list. Wal-Mart claims the top spot again. See who made the list.

Change The World

Impact Segment

Sector

Key Financials (last Fiscal Year)

Revenues ($M)

Profits ($M)

Assets ($M)

Total Stockholder Equity ($M)

Profit Ratios

Profit as % of Revenues

Profits as % of Assets

Profits as % of Stockholder Equity

Earnings Per Share (last Fiscal Year)

Earnings Per Share ($)

EPS % Change (from prior fiscal year)

EPS % Change (5 year annual rate)

EPS % Change (10 year annual rate)

Total Return

Total Return to Investors (last year)

Total Return to Investors (5 year, annualized)

Total Return to Investors (10 year, annualized)

Best Companies To Work For Europe

CEO/Top executive

Group headquarters

HQ location

GPTW national list

Woman CEO

Number of Years on List

Q2 2026

Q1 2026

Q4 2025

Q3 2025

Q2 2025

Q1 2025

Q4 2024

Get insights into Zoetis including business profile, stock information, news, and rankings from Fortune.

Zoetis (ZTS): Company Profile, Stock Price, News, Rankings

legacy

Zoetis

zoetis

Welcome to the First Quarter twenty twenty five Financial Results Conference Call and Webcast for Zoetis. Hosting the call today is Steve Frank, Vice President of Investor Relations for Zoetis. The presentation materials and additional financial tables are currently posted on the Investor Relations section of zoetis.com. The presentation slides can be managed by you, the viewer, and will not be forwarded automatically. In addition, a replay of the call will be available approximately two hours after the conclusion of this call via dial in or the Investor Relations section of zoetis.

In the interest of time, we ask that you limit yourself to one question and then queue up again with any follow-up questions. Your line will be muted when you complete your question. When posing your question, please pick up your handset to allow optimal sound quality. It is now my pleasure to turn the floor over to Steve Frank. Steve, you may begin.

Thank you, operator. Good morning, everyone, and welcome to the Zoetis first quarter '20 '20 '5 earnings call. I am joined today by Kristen Peck, our Chief Executive Officer and Whitney Joseph, our Chief Financial Officer. Before we begin, I'll remind you that the slides presented on this call are available on the Investor Relations section of our website and that our remarks today will include forward looking statements and that actual results could differ materially from those projections. For a list and description of certain factors that could cause results to differ, I refer you to the forward looking statements in today's press release and our SEC filings, including, but not limited to, our annual report on Form 10 ks and reports on Form 10 Q.

Our remarks today will also include references to certain financial measures, which were not prepared in accordance with Generally Accepted Accounting Principles or U. S. GAAP. A reconciliation of these non GAAP financial measures to the most directly comparable U. S.

GAAP measures is included in the financial tables that accompany our earnings press release and the company's eight ks filing dated today, Tuesday, 05/06/2025. We also cite operational results, which exclude the impact of foreign exchange. With that, I will turn the call over to Kristen.

Thank you, Steve, and welcome everyone to our first quarter twenty twenty five earnings call. By staying laser focused on delivering for our customers, our colleagues drove strong 9% organic operational revenue growth and grew adjusted net income 6% on an organic operational basis. Our International segment led with 11% organic operational revenue growth, highlighting our global scale and diversification, while The U. S. Grew 6% excluding the impact of the MFA divestiture.

Growth was balanced across species. Our innovative companion animal portfolio grew 9% operationally, fueled by sustained demand for our diverse market leading franchises. Livestock grew 7% on an organic operational basis, driven by broad based double digit performance internationally. Before we go deeper into the quarter, I want to briefly address what is top of mind for many of you. In today's operating environment, the essential nature of our business remains clear.

Animals provide companionship and nourishment, and in uncertain times, people will rely on both. It's precisely because of the enduring secular trends and the fundamentals underpinning our innovation led operating model that Zoetis has consistently proven its resilience even through economic turbulence. That resilience is embedded in how we operate, from our global footprint and diverse durable portfolio across species and geographies to our omnichannel presence, matrix manufacturing network and talented field force. Combined, those dynamics ensure we're operating from a position of strength as we navigate a fluid environment shaped by macroeconomic, regulatory and geopolitical uncertainty. We are managing these challenges thoughtfully, working to minimize their impact while also seizing opportunities where they exist so we can continue delivering for our customers, colleagues and shareholders.

That means executing our strategy with discipline, supported by a strong balance sheet, operational excellence, thoughtful and strategic capital allocation and experienced leadership team ready to adapt as needed. Most importantly, we continue to prioritize what matters most, living our purpose and ensuring our products reach the people and animals who depend on them. With that context, let's pivot back to the quarter. While our performance reflects the strength of our diverse multi levered strategy, I'll touch on a few of the key growth drivers. In Companion Animal, our combined key franchises grew double digits operationally, fueled by exceptional performance in our international segment, where our trusted brands, even after several years on the market, continue to grow by winning new patients and improving compliance with significant runway to further define the standard of care and deliver meaningful outcomes.

In parasiticides, our Simparica franchise continues to expand the overall category and is gaining share driven by our omni channel strategy, meeting customers where they are, whether in the clinic, through retail, where Simparica Trio is the top selling parasiticide in The U. S. Or via home delivery. As you've heard us say, we are seeing increased conversion to broad spectrum triple combinations, setting us up for an even longer term growth tailwind. Together, these dynamics positions us well to continue leading through innovation, most recently with Simparica Trio's U.

S. Label expansion to include flea tapeworm protection. Similarly, key dermatology has consistently been a high growth category built on innovation, customer trust and a portfolio that remains the preferred choice for treating allergic itch. Through years of investment and strong partnerships, we have built brand loyalty and established a clear leadership position. We continue to leverage our first mover advantage by capitalizing on the breadth of our portfolio to grow and sustain share in a dynamic environment.

We remain focused on what we can control, execution, innovation and customer experience, and we are winning with customers every day. Demand for our portfolio remains strong, fueled by the convenience and the unmatched flexibility we provide to vets and pet owners through our three differentiated products. At the same time, an estimated 20,000,000 dogs still untreated or undertreated for itch. Advances in diagnostics are helping unlock this opportunity, enabling broader access, earlier intervention and better outcomes. That's why we're confident in the enduring strength of this franchise and our ability to continue leading.

And similarly, building on our track record of scientific innovation, our osteoarthritis pain franchise marks a meaningful advancement in care, delivering strong double digit growth and approximately 25,000,000 doses distributed globally. While adoption has been more gradual than initially expected, we are encouraged by the foundation we are laying and the long term potential ahead. We are building and scaling a new category of care, one that requires significant education and engagement. Both veterinarians and pet owners need time and support to fully understand the safety and efficacy profile of newer, more advanced treatments for chronic pain. And in this economic environment, we're seeing pet owners take a more measured approach to managing chronic conditions, making choices that reflect broader consumer spending trends, which could include adjustments to timing or frequency of care.

That said, we see the impact of these therapies every day. They are safe, effective, and improving the quality of life for pets and the people who care for them. To accelerate adoption, improve access, and grow the OA pain market, we are taking focused strategic actions. We are expanding medical education for veterinarians and partnering with key opinion leaders to shape best practices. We're investing in and plan to leverage post launch studies to generate additional real world insights for vets.

We are engaging directly with pet owners to increase education on the burden of OA pain and the long term value of treatment. And we are launching three sixty campaigns, including targeted direct to consumer efforts to build awareness and demand. So uptake may be slower in the near term, our long term confidence remains strong as we build a durable, differentiated market with significant room to grow, especially given the sizable and underpenetrated opportunity ahead. In livestock, we delivered strong performance with 7% organic operational growth. Through the sale of our MFA portfolio, we consistently reaffirmed our commitment to livestock and our customers because what makes Auetis unique and reliable is the diversity and durability of our business model.

Regardless of portfolio mix, one thing is true, people need to eat and global demand for animal protein will continue to rise. That's why we continue to invest in solutions to protect the health of food producing animals and safeguard supply chains. Since reporting our results in February, we received conditional licensure from the USDA for avian influenza vaccine for chickens, ensuring we are ready to support customers and regulators wherever the path leads in addressing this evolving threat. And it's during periods of uncertainty that execution matters most. Our experience enables us to rise to the occasion, to stay focused, stay ready and continue delivering solutions where and when they are needed most.

As we look to the rest of the year, we're encouraged by our first quarter performance and the steady demand for our products, along with the resilience we've consistently seen across the animal health industry. We are maintaining our full year organic operational revenue guidance range of 6% to 8%, reflecting confidence in the differentiation of our portfolio and our ability to execute in the current environment. While the operating backdrop remains unpredictable, we believe this range appropriately reflects what we know today and we will remain agile in navigating new uncertainties and embracing new opportunities. At the same time, based on our current estimates of enacted tariff related cost impacts, we are updating our full year organic operational adjusted net income to a range of 5% to 7%. And just to clarify, our outlook does not include any potential impact from future tariffs as it's still too early to know how the situation will unfold.

And with that, I will close with this. The performance we shared today reflects the dedication of our colleagues around the world, living our purpose, being a trusted solutions provider to our customers, and delivering results through their relentless focus. Uncertainty is top of mind for everyone, but it's not unique to Zoetis. What sets us apart is how we respond. Zoetis has consistently leveraged its innovation led customer first operating model to outperform the market and deliver value for both customers and shareholders.

We remain vigilant and agile. We'll draw on our experience navigating complexity, stay clear eyed in our decision making and continue moving forward with discipline. We are confident in the strength of our portfolio, in the promise of our pipeline, in our ability to adapt. Most of all, we're confident in the commitment of our teams around the world to lead through change and continue delivering for our customers and shareholders, Because ultimately, what we do matters for the well-being of animals, people, and communities. That's why animal health is both essential and resilient, an industry fueled by long term demand and rising expectations for high quality care.

And as a global leader, we recognize our responsibility to lead today and well into the future. With that, I'll turn it over to Wetteny to walk us through the more detailed financials. Wetteny?

Thank you, Kristen. In the first quarter, driven by balanced portfolio growth, we posted $2,200,000,000 in revenue, growing 1% on a reported basis and 9% on an organic operational basis, which excludes the impact of foreign exchange and the MFA divestiture. Our organic operational growth was driven by 4% price and 5% volume. Adjusted net income of $662,000,000 grew 4% on a reported basis and 6% on an organic operational basis. Our companion animal portfolio led the way with $1,500,000,000 in revenue, growing 9% operationally.

Globally and on an operational basis, our Simparica franchise contributed $367,000,000 growing 19%, key dermatology posted $387,000,000 growing 10%, and our OA pain mAbs reported $147,000,000 growing 15% in the quarter. Our Lifestyle portfolio also contributed organic operational growth of 7% on $645,000,000 in revenue. Now moving on to our Q1 segment results. U. S.

Revenue grew 2% on a reported basis and 6% on an organic operational basis in the quarter, with companion animal growing 8% and livestock declining 2% on an organic operational basis. In companion animal, U. S. Growth was driven by our three key franchises, while vaccines faced headwinds from supply timing coupled with competitor reentry. Across the portfolio, alternative channel sales continued to outpace the vet channel, offering greater convenience for pet owners, improving compliance and stickiness.

Driven by strong growth in auto ship programs that boost compliance and increase the lifetime value of each dog on treatment, our Simparica franchise posted 17% U. S. Growth this quarter on $260,000,000 in revenue. Additional competitive entrants are accelerating the market shift to triple combinations, where we continue to gain share, thanks to the strength of our field force, our first mover advantage and ongoing innovation, including expanded label claims. In key dermatology, sales were $249,000,000 up 7% with growth across both Apoquel and CYTOPOINT, while also reflecting the comparison to last year's initial distribution stocking of Apoquel chewable.

APOCOL growth continues to be driven by the retail channel and continued conversion to the chewable, which is easier to administer and promotes daily compliance. Our OA pain mAb, Librel and Silentia posted a combined $65,000,000 in U. S. Sales growing 14%. Librela grew 17% on $47,000,000 in revenue and Silentia posted $18,000,000 in revenue growing 7%.

To reiterate Kristen's point, building a new category of care takes time, but we remain confident in the sizable market potential. Our foundation is solid, and record penetration confirms that veterinarians want better OA solutions. Organic operational declines of 2% in livestock are primarily driven by declines in Jackson due to aggressive price competition and the timing of price adjustments in the prior year, as well as the timing of supply of Ceftifure. Moving on to our international segment, revenue was flat on a reported basis and grew 11% on an organic operational basis. Companion animal grew 10% operationally and livestock grew 12% on an organic operational basis.

Similar to The US, international companion animal sales were driven by strong performance in our Simparica, key dermatology and OA pain franchises. Our international Simparica franchise, including Simparica and Simparica Trio, grew 23% operationally on $106,000,000 in sales, with both brands driving strong market share gains. Simparica grew 22% operationally on $61,000,000 in sales, driven by expansion of the combination parasiticide market, especially in Latin America and Eastern Europe. Emparica Trio contributed $46,000,000 growing 26% operationally with strong performance across all regions. Our key dermatology franchise delivered 138,000,000 in revenue, up 15% operationally with double digit growth in both Apoquel and Cytopoint.

Our performance was driven by field force engagement with vets, leading to new patient starts and improved compliance, especially among chronic cases. As Kristin highlighted, we're executing globally on our key derm strategic priorities. We continue to show strong progress driven by continued conversion of Apoquel chewable, which now accounts for 57% of doses in Europe. Internationally, our OFA mAb were 16% operationally, posting $82,000,000 in combined revenue. International sales of LUBRELLA were $65,000,000 growing 14% operationally.

Our international efforts have had a significant head start over The U. S. As we enter our fifth year in some markets. We continue to drive double digit sales growth and expand both the market and our share. Valencia sales were 18,000,000 growing 27% operationally in the quarter.

Let's see now holds over half of the feline OA market share in international markets, underscoring the strong demand for an OA solution for cats. International livestock grew 12% on an organic operational basis in the quarter. Growth was driven by higher price, including some impacts from high inflationary markets. Volume growth, excluding the impact of MFAs, was driven by poultry vaccine growth from key account penetration across Asia, The Middle East and Latin America. Cattle contributed to growth with a return to a more normal environment in Australia, as well as strong demand across much of South America, Canada and Mexico.

Our fish business saw good vaccine growth across geographies. Now moving on to the P and L for the quarter. Adjusted gross margin of 72.1% grew 140 basis points on a reported basis. Foreign exchange had a favorable impact of two twenty basis points. Excluding FX, we saw lower margins due to higher manufacturing costs, in line with our expectations and included in our initial guidance in February, which should improve as we work through inventory value that prior year standards and unfavorable product mix.

This was partially offset by the favorable impact of our MFA divestiture. Adjusted operating expenses increased 3% operationally. Growth was driven primarily by SG and A increases of 4% operationally, mainly due to higher compensation related expenses and increased direct to consumer advertising. R and D declined 2% operationally this quarter due to lower project spend primarily due to timing. Adjusted net income grew 2% operationally and and 6% on an organic operational basis.

Adjusted diluted EPS grew 4% operationally in the quarter and 8% on an organic operational basis, 2% higher than adjusted net income and reflective of a lower share count as a result of our ongoing share buybacks. Before we get into guidance, I'll expand on the business impact of the tariff landscape. While the current situation remains fluid, we are well positioned to navigate this dynamic environment. We'll be thoughtful and deliberate in our actions with a clear focus on both near and long term goals. We will leverage the diversity of our revenue across geographies and species to seize opportunities for growth, ensure we work to control expenses, price strategically and manage inventory.

People and animals depend on our products, and we will continue to deliver for customers. Now moving to guidance for the full year 2025, which reflects continued confidence in our operating model, while acknowledging that there will be some profitability impact in the near term due to enacted tariffs. Please note that guidance reflects foreign exchange rates as of late April. For the year, we are guiding revenue between $9,425,000,000 and $9,575,000,000 with increases due to favorable foreign exchange when compared to the late January rates used in our initial February guidance and maintaining organic operational growth of 6% to 8%. We recognize that there are external factors that are beyond our control.

As such, our current guidance does not include any assumed impact of future tariffs, policy changes or further worsening of the macro environment. We continue to expect broad based operational growth across our Simparica, key dermatology and OA pain franchises and reiterate our expectation that these combined innovative franchises will grow double digits in 2025. We now expect adjusted net income to be in the range of 2,775,000,000 to $2,825,000,000 reflecting operational growth of 5% to 7% on an organic operational basis. Our revised adjusted net income guidance is reflective of the estimated impact of current enacted tariffs, while not accounting for any future changes in the tariff landscape. Lastly, we expect adjusted diluted EPS to be in the range of $6.2 to $6.3 and reported diluted EPS to be in the range of $5.85 to $5.95 This EPS increase is primarily due to favorable foreign exchange compared to the late January rates, as well as the reduction in our share count due to share repurchases in the quarter, slightly offset by enacted tariffs.

As we indicated in February, our EPS projections are based on current share counts and do not consider the future favorable impact of our ongoing share repurchase program. As we look forward to the remainder of the year, we recognize there is a degree of uncertainty, but we remain confident in our outlook. In the past, our proven diversified model has delivered steady, predictable and meaningful growth through dynamic environments. We lead into attractive end markets with strong fundamentals, have a portfolio of market leading franchises, a sustainable stream of innovation and a proven track record of execution. Now, I'll hand things over to the operator to open the line for your questions.

Thank you. We'll hear first from Erin Wright with Morgan Stanley. Please go ahead.

Great. Thanks. So first on I'll do Librela first and and then tariffs. I guess, you speak to what you're seeing across The US market in terms of the Librela label change, how that's a responding relative to your expectations there? And how do you think the longer acting OA pain product could potentially replace or enhance sort of the OA pain offering, as we head into potentially next year?

And then on tariffs, can you describe what exactly is embedded in terms of the growth tariff impact and what mitigation efforts you have? And then and then what does it mean when you say enacted tariffs? I guess, what tariff or jurisdictions are you incorporating, or product categories? Do you where do you have, I guess, the most exposure, and and what sort of is is the tariff impact now embedded in guidance? Thanks.

Sure. Thanks, Erin. I will take the Librela question. I'll let Wetteny take the tariff question when I'm done. As we as Wetteny sort of mentioned in his prepared remarks, we had about 15%, organic operating growth in Librela across the globe with in The U.

S. Having about 17%. We're continuing to grow the market and vet satisfaction remains strong. Our focus right now is on building and scaling the new category of care and really focusing on continued education and engagement. Now that the label is settled, we're really focusing on expanding our medical education.

We're investing in a number of post launch studies as we've talked about to generate more real world data. We're also bringing in some key opinion leaders from Europe who've had the product for over five years to share their experiences in The U. S. As well as investing in targeted DTC. So we continue to have long term confidence.

It remains strong. And, you know, we we really think Librela is, you know, meeting a significant unmet medical need, and remain excited. Wetteny, do you wanna, cover the tariff question?

Sure. Look, Aaron, our guidance today reflects the net impact of the tariffs that are actually already in place. And so that's net of any mitigations that we've already, put together, here, although the situation remains fluid. To give you a little bit more color in terms of where the exposure is and what what we have reflected today, This is primarily from imports related to APIs, for a few of our livestock products, coming from China. And then some impact from few of our diagnostics, products as well as certain veterinary accessories.

Zooming out, the situation remains fluid, obviously. And we continue to monitor as well as are actively planning various scenarios depending on where, tariffs land. Keep in mind, we have a broad diversity of geographic footprint, and 60% of our manufacturing footprint is actually in The US. So we export more out of The US than we import into The US. And particularly, when you think about companion animal, vast majority of our sales are actually produced in The US for those.

And a a good portion of the companion animal sales outside The US are actually produced in The US. And so I think when you think about that, our exposure is really, likely more from retaliatory tariffs from other jurisdictions. So our most of our exports go to Europe as well as our imports are actually coming from Europe. So you think about that in the context. And, course, we continue to monitor those.

Given our supply chain as broad as it is, that gives us lots of, mitigation opportunities. So we until we know exactly what, where tariffs land, we won't know exactly how much we'll mitigate, but we do feel confident that our footprint allows us quite a bit of flexibility to do that. Those will range in terms of time frame where they can be executed, from immediate where it may be moving our inventories all the way to longer term in terms of what does that mean in terms of our footprint. So lots of opportunities for us as we look at that. But given our diversity from a geography product, etcetera, standpoint, we feel we are as well positioned to navigate this as anyone else.

We'll hear next from Michael Ryskin with Bank of America. Please go ahead.

Great. Thanks for taking the question guys. I'll start on the competitive side of things. I think, Wetteny and Kristen, you guys both called out competitive entrants a little bit more in your prepared remarks. Obviously, you've got you've had NextCar Plus in the market for a while now and also Credelio, Quattro and Zynbrellia.

Just if you could dive into a little bit more of like where are you seeing the most competitive pressure? How is it taking shape? Is it more in terms of price? Anything you're seeing in terms of pre stocking, pre selling? There's a derm competitor expected later this year as well.

So just sort of what have you seen so far? What are you factoring into your guide from the competitive side of things in those categories? And then a follow-up on Librela, on Aaron's question there. I just want to now that you've had the label change and some of the learnings from the last couple of months, is your assumption for fiscal year twenty twenty five Librela any different than it was before? Do you think you'll be able to offset some of these as you go through the year?

Just wondering if your thoughts on the ramp for this year are any different than they might have been three months ago? Thanks.

Okay, great. I'll start on the competitive side and then let Whitney build off of it. I mean, I think what's really important to note in both dermatology and parasiticides is we were the first mover. And I think that's really important because especially if you look at parasiticides, being the first mover made a big difference. Really, we've just been growing our share over time as we talked about.

You know, we obviously had one of the biggest competitors enter, you know, over a year ago, and we're printing 19% growth overall, for the quarter in in Trio. So I think that's incredibly strong. I I think what we're really seeing is that there's still 40% growth in a combined flea tick heartworm space. And the more people that enter, the more, you know, people get switched into combo therapies from, you know, single therapies or topicals or collars. So, you know, we continue to see that, regardless of who is entering.

You know, we have excellent product. It's continued to compete really well in the market. We're really proud of the execution on this in The U. S. And around the globe.

So we've seen competition. We're obviously going to continue to see more competition. I think what's also know, something to focus on is that right now, we have a 40% share in puppies. And, you know, obviously, once one dog goes on a product, it's, you know, rare that it'll switch. So I think that's a really good indication of where that's going in the future.

As we talked about, we are expecting potentially a new competitor in dermatology. What you can get into the specifics, that's baked in. But, again, I'd say, you know, if you look at dermatology, we have three excellent products that have been in the market, you know, for a long time that are accepted that, you know, that have an over ninety percent satisfaction rate with those products, and we are the first mover. So I'll let Whitney talk about what that means in guidance, etcetera, and then if you wanna follow-up anything else on the umbrella if you want, Whitney.

Sure. If you look across our three key franchises, and I think this will cross over both your first question on competitive entrance as well as, your question on Librela, and I'll double click on that a little bit, Mike. So first of all, our large three key franchises, we expect to grow double digits, in 2025. They delivered 14% in the first quarter and remain double digits in our guidance. I think if you look at these, areas, including those, that already have competition or where we expected we expect more entrants, to come in.

The bigger picture is the opportunity that remains. I think in every area, you have large markets even at the current sizes. In derm, we still have $20,000,000 that are undertreated or untreated. And clearly, with double digit growth, in that category, a decade plus later, we're we are accessing, those expansion opportunities, and we have more to go, particularly when you think about international. If you look at Librela, again, our key franchises are are double digit expectations for the year.

We haven't given specific guidance consistently with the first guidance in February on a particular product. But I think I would share this. We had a very strong launch to this product in terms of penetration in clinics in The U. S, etcetera. If you look at that, that's a strong foundation for us.

And really, you look at the feedback from vet, they remain very strong in terms of satisfaction. And so with twenty seven million medicalized dogs in The U. S. Alone with OA and only nine million being treated, 8,000,000 needles on NSAIDs and one million on on Librela, I don't think I need to spell out just how vast the opportunity is, and we're still early. And clearly, as the adoption curve is lower than we expected, as we said in the prepared commentary, we are doubling down on efforts to drive education and awareness, etcetera.

The industry has seen this before with other products. We've seen this before and we're confident in terms of the long term opportunity here and our position in it as a first mover and the impact it's making on dogs across the world. So we'll continue to drive those.

Yeah. And the other thing I'd say is, you know, we're really seeing this as, you know, a huge market opportunity of the future. You know, we've talked for a while that we think the overall market opportunity for us in a way is between 2,000,000,000 and $3,000,000,000. And we're investing, as you know, in a long acting, o a monoclonal antibody that as we mentioned earlier in the year, we are expecting approval for, this year. This would be a long acting three month, injection.

It is a new and different antibody than Librela with the unique binding site, and we're expecting the dosing range to be about 10 times lower than Librela. So, you know, obviously, we have a lot of confidence in continuing to grow this market and the potential for this market given all the things that Whitney said, and we'll continue to invest in life cycle innovation, behind Librela as well.

We'll hear next from Jon Block with Stifel. Please go ahead.

Great. Thanks, guys. Good morning. Hope you can hear me okay. Maybe just building on a couple of the prior questions.

What we just pretty straightforward, but can you just maybe help us and bridge us to the 20¢ increase to the 2025 EPS guidance because just, you know, obviously back of the envelope. But even with the advantageous move in FX, the lower interest expense, and the lower shares, I'm actually having a hard time getting to 20¢ and that's arguably before any tariff headwind. I don't know if you can give us, like, a gross, you know, or, net tariff impact, on that side of the equation. And then, Kristen, I guess, just a little bit more on Librella. Pretty direct question.

Do we assume or should we assume flat U. Librella revenue for the next two to three quarters until the long acting is out there? I think the targets here in '25, give or take. Is there anything called in the near term to reaccelerate The U. S.

Librela revenues before the long acting? And then I know you just gave some helpful information on the long acting. Is that going to carry, call it, a different brand versus Librela? Thanks, guys.

Yeah. Sure. Look, John, I'll take the the bridge to the EPS raise, in dollars for you. If you go back to our initial guidance in February, which, used rates, from late January versus where rates are, as of late April. We are seeing, initially, what we, guided to was about a $200,000,000 headwind related to FX on a reported basis.

And that was really reflective of the dollar that strengthened, particularly in the second half of twenty twenty four. If you look at where rates are at the April, largely driven two thirds of this change is driven by the euro, the pound sterling, and the yen. You are looking at most of that, not all of it, nearly all of it actually, being reversed with the weakening dollar. So that is largely, if not entirely, what's driving the EPS, change that you see from us, driven by FX. And I would tie this also with trade policy and tariffs and so on.

So we talk a lot about the impact that has on the organic operational, but it does have, somewhat of the opposite effect in terms of what is going to the dollar and demand for that. So I do wanna make sure that that is, at least, looked at, and recognized. And so the the impact you see is here. Now in terms of tariffs, net of mitigations, we're calling about $20,000,000, of of headwind that we're putting here. And keep in mind, in February, we said we did not reflect tariffs and we would do so as we know more.

And based on what's enacted, we have that reflected here today. But for that, our organic operational growth in adjusted net income would be the same as it was in February. Again, I'll give you a little bit more color in terms of what that impact is, and I gave you some more in terms of where how we're positioned as we continue to monitor the situation and where we have mitigation opportunities, as we look ahead. Hopefully, that helped in terms of the FX. I do think what you're going to see is it's flat beef near flat for the year now, with headwinds in the first half and tailwinds in the second half based on where rates are.

Again, we don't forecast the rates. We're simply using the spot rates as of late April and and assume they stay where they are, which we know they won't. This would be the impact. And so that is consistently how we have, reflected on FX.

So I'll follow-up with your question with regards to Librela. I as you know, we obviously don't give quarterly guidance. But as I mentioned earlier, we are obviously investing to continue to grow and scale this product, throughout the year. We're doing all the things we mentioned, you know, obviously, the medical education, the DTC, we're obviously investing in many post launch studies to generate real world data. You saw a few of those come out right now.

We provided our pharmacovigilance data to Frontier's journal, which indicated that all individual events are both rare and very rare. We also did a Librela meloxicam, which had 17 AEs for meloxicam and four for Librela. We're continuing to invest in additional real world studies to support the brand. So we are investing, obviously, to grow this brand. We are not waiting for growth until we get a long acting monoclonal antibody.

And I think you also said it will obviously have a different brand. It is a unique antibody. And so obviously, therefore cannot share the brand of Librela given its unique molecule. So that would not have the same branding. But look, we can I just wanna reiterate?

This is a 2 to $3,000,000,000 market. We are only 1,000,000 right now on the product. There's 9,000,000 treated in The United States. But I'd argue, by the way, there's 27,000,000 dogs with OA. So beyond even what's treated today, there's an untreated, market as well, so as you look at this.

So we see this as a significant opportunity that we're going to continue to invest behind.

We'll take our next question from David Westenberg with Piper Sandler. Please go ahead.

Hi. Thanks. I'm gonna actually get away from the library of questions. So Amazon is, now selling some of the online drugs probably. I think it's just singles right now, but maybe get a broad spectrum.

Can you talk about any changes in your sales or sales and marketing efforts, both in terms of educating vets or direct to consumer strategies? And with Amazon, do you see an acceleration of trends to the alternative channel, or do you think this is just maybe more market share taking and it would just see the same exact acceleration or the same exact, trends we've seen? And then just a really quick one on the FDA and particularly the CMV. Can you tell whether or not there is any potential backlogs or delays in the FDA? I know that the actual reviewers, there hasn't been any cuts in order to that.

But I mean, I think there would be some maybe in some of the support staff that might have like maybe a downstream effect. Thank you.

Sure. I'll start with your second question first. Yes, we are obviously monitoring any changes to both FDA and USDA, closely. There are obviously work cuts, already at FDA, but we have not seen any slowdowns, on any of our pipeline products as we talked about. We have a very robust pipeline.

We work very closely with the FDA. And look, we're working very closely with the administration, with Congress, and with the regulators to help shape that evolving environment. We're looking for opportunities to support their efforts on efficiencies while supporting innovation. We think there's lots of opportunities to speed innovation and I've spent a lot of time in DC working with them. You know, we really think that innovation is critical as you think about, you know, the the food supply chain as well as public health, as well as, you know, really, you know, bringing unmet products, to market.

So, it's a real focus of ours here. We have not seen any slowdown in any of our pipeline products currently at the FDA or the USDA, but we are spending a lot of time there making sure we continue to shape this environment. The second question was on retail growth. I'll start there and see what Wendy's got to build on it. First, I'd underscore that retail in the quarter grew 40%.

That was, you know, obviously, there's a little bit there on some one time stocking, so what you can get into that. But right now, retail is 21% of our US business, and this has been growing every year. So I mean, I think Amazon just one more. But, Wendy, you want to get into some of the specifics there?

Yeah. I'd be happy to. I think to your point, if you look at retail and and when we talk about alternative channels, we have both retail and home delivery, which we're seeing traction there as well. If you look at our retail, in the quarter about 40% growth, some of that as we talked about, in February, we saw a little bit of inventory decrease at the December through the holiday season. Some of that picked back up in January, so a little bit crossing over, there.

But overall, the trend line continues in terms of the strength that we've seen there. When I zoom out, and I think we talk a lot about diversification in this company. Right? We talk about product categories, geographies, species, etcetera. I do think alternative channels, also presents another level of diversification.

We're certainly positioned well to meet the consumer wherever their channel of choice is, and that includes in the clinic. And when products move from the clinic to, these alternative channels, we're positioned to capitalize on those as well. So I think any move by any party, Amazon or anyone else, is going to continue to give more choices to the consumer and our products are available to them to really drive that. And I think from an economics perspective, we talked about on this call before, they are neutral to positive versus the overall. So so this is another area that we're well positioned to continue to capitalize on, in terms of where our products are.

And I think that we'll also continue to grow, the compliance for most of our key products. And, you know, we've got significant percentage of our sales currently for both Apoquel and Simparica Trio, over 40% of both, in the retail channel. So, I think, you know, Amazon is just one more entrant there.

We'll hear next from Brandon Vasquez with William Blair. Please go ahead.

Hey, everyone. Thanks for taking the question. Kristen, you made a comment about, on the Librela side that maybe consumer sentiment or consumer spending was weighing a little bit maybe on compliance. Can you just talk a little bit about what you guys are seeing through April given kind of consumer sentiments rolling over a little bit, not just in Librela, but just the broader portfolio? Are you seeing meaningful changes in compliance across the board or not?

And just kind of the feeling as we're going through the second quarter. And then one quick model follow-up question. Let me, can you just talk about what price and mix price and volume expectations are for the rest of the year as well? Thanks.

Sure. Yes, I think what we talked about in, our prepared remarks is obviously adoption, has been more gradual as you look at sort of the OA pain market. And honestly, some of the more expensive chronic medications right now than we probably initially expected. But look, we're really encouraged by the foundation that we're building. We are starting to see in small pockets a more measured approach to managing chronic conditions.

I think consumers are making choices that reflect sort of broader consumer trends. But I think what's great about our portfolio is how broad it is across so many different categories. So if maybe the most expensive, we also you can look at it in Apoquel, if you're looking at the derm space. And we're continuing to see incredibly strong growth right now in wellness. So, you know, as we always say, we see the animal health industry as incredibly durable and recession resistant.

Obviously, we're not recession proof. And I think what really sets Zoetis apart in this is that we're more resilient than the industry given the innovation that we bring to market. We have really disruptive, products that meet unmet medical needs. And if you look at a growing global population, whether that's, you know, on the food side or in the companion animal side, I think, you know, Zoetis has always whether these, better than others, and we believe we'll continue to do so. Wenya, you want to take the second question?

Sure. Look, up price and volume mix is consistent with how we saw them coming into the year. And I'll remind you of a few points here. In 2024, we saw strong volume growth, particularly across our key franchises, even as we saw price elevated the last couple of years to the tune of 5% to 6%. We came into this year saying we expect price to be above our historical 2% to three but below those levels from the last couple of years.

And you saw that play out in the first quarter. Our volume growth out of the 9% organic operational growth was 5% volume and 4% price. Now I would say the direction of travel for the rest of the year would be consistent in terms of that mix. And one last note is last year we saw, higher contributions from our hyperinflationary markets, particularly when you think about livestock in international, where we're seeing much less of that, though we're seeing some, in the first half, in the first quarter here, much less of that, this year versus what we saw last year.

Zoetis (ZTS) Q1 2025 Earnings Call Transcript

Company Participants